Once For All to Acquire Nalanda Global
4.4.2024 09:00:00 EEST | Business Wire | Press release
Once For All (the “Company”), a European leader in supply chain compliance and sustainable sourcing solutions for the built environment, is excited to announce the acquisition of Nalanda Global (“Nalanda”), a leading supply chain risk and compliance management software platform in Spain.
The transaction extends Once For All’s European footprint into Spain and enhances the differentiated offering of its technology platform, adding scale and the ability to aid in providing a broader product suite to its customer base. Similar to Once For All, Nalanda operates a SaaS-based network that helps enable contractors in multiple industries to manage the compliance of sub-contractors in their supply chain. Nalanda also brings additional worker-level compliance and health & safety solutions to Once For All’s product suite.
Founded in 2000 by a group of preeminent Spanish construction companies, Nalanda is based in Madrid, Spain, and its international presence currently extends across more than ten countries in Europe and Latin America. Its solutions are used by large companies across a variety of engineering-related sectors including construction and facilities management. With a network of over 1,000 contractors and 45,000 sub-contractors as of December 2023, Nalanda has one of the largest digital communities of suppliers globally.
GTCR, a leading private equity firm, acquired Once For All in 2023 in partnership with Chief Executive David Hornsby. PSG Equity, a growth equity firm that partners with software and technology-enabled services companies, acquired a majority stake in Nalanda in 2021. As part of the transaction, which is expected to close in the coming weeks, the PSG funds will retain a minority stake in the combined business.
David Hornsby, Chief Executive of Once For All, said:
“Nalanda is a well-established provider with a product suite that strategically complements our own, and we are enthusiastic about combining our strengths as we continue to grow Once For All across Europe. We are excited to welcome the Nalanda team to Once For All and we look forward to working together.”
Juan Gil Rabadan, Founder and CEO of Nalanda, said:
“Nalanda has gone through a transformative journey over the last three years under PSG’s ownership. Through the investment in people and product, both organically and via M&A, we’ve established Nalanda as an industry leader in supply chain risk and compliance management in Spain, with a growing international presence. We are now thrilled to join Once For All as we share a vision for supporting the built environment globally. We look forward to partnering with the Once For All team and continuing to invest in innovating our technology and capabilities to serve our customers.”
Mark Anderson, Managing Director and Head of Technology, Media & Telecommunications at GTCR, said:
“The combination of Once for All and Nalanda helps position the business for future growth through a pan-European offering. The combined company provides a leading technology platform and differentiated suite of products to help address the critical supply chain and compliance needs of its customers. We are pleased to partner with the PSG team and look forward to the continued success of the business.”
Dany Rammal, Managing Director at PSG Equity, said:
“PSG is proud to have been part of the journey to create a leading Spain-based software champion. Nalanda’s success to date is a testament to Juan Gil Rabadan’s vision and his entire team’s dedication to scaling the Company’s solution into a comprehensive supply chain risk management and compliance offering. We are excited to be continuing the journey alongside GTCR, David Hornsby and the entire Once For All management team in support of the combined company’s growth journey.”
About Once For All
Once For All is a European leader in supply chain risk management and sustainable sourcing solutions for the construction industry. We help our customers source and track sales opportunities, manage risk and compliance, and provide tools to increase efficiency in their supply chains. Once For All has over 150,000 customers that use its single codebase SaaS solution to search, find and assess future business relationships based on skills, trades and ESG credentials. As a result, Once For All manages one of the largest proprietary ESG data sets in the world. Once For All has over 400 employees, is the market leader in UK and France and has operations in Belgium and Germany. For more information, please visit www.onceforall.com.
About Nalanda Global
Nalanda is a Spanish supplier risk and compliance management platform founded in 2000. It leverages intelligent cloud software to help connect companies and suppliers using a digital platform that enables the smooth exchange and verification of health and safety, due diligence, supplier validation, invoices, ESG and other business information, as well as providing solutions designed to ensure compliance with worker access, and working time. Nalanda operates in Spain, as well as in several European and Latin American countries. For more information, please visit www.nalandaglobal.com.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
About PSG Equity
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 135 companies and facilitated 479 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403942729/en/
Contact information
Once For All
Arun Varma
arun.varma@onceforall.com
Nalanda
Goodwill Comunicación
Javier Herreros
jherreros@goodwill.es
GTCR
Andrew Johnson
Andrew.johnson@gtcr.com
PSG Equity
Prosek Partners
Matthieu Roussellier/Kate Pledger
Pro-psg@prosek.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom